Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13

In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.

R T Mulcahy, D W Siemann, R M Sutherland
PMCID: PMC2010495  PMID: 7459244

Abstract

Female C3H/HeJ mice bearing intramuscularly transplanted KHT sarcomas were treated with a single dose of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, 30 mg/kg, i.p.) alone or in combination with a single dose of misonidazole (MISO, 1.0 mg/g, i.p.) or its desmethylated metabolite Ro-05-9963 (2.0 mg/g, i.p.). The effectiveness of drug therapy was assessed by a tumour growth-delay assay (i.e. measuring the median time required for tumours to grow to treatment size x 4). The relative efficacy of administering the nitroimidazoles in various schedules ranging from 12 h before to 12 h after BCNU administration also was evaluated. Untreated control KHT tumours grew to the initial size x 4 in a median time of 4 days. No significant growth delay was seen in mice treated with either nitroimidazole alone, whilst treatment with BCNU alone produced a median growth delay of 7 days. Combination chemotherapy with 9963 administration 3 h after BCNU significantly increased the median tumour growth delay to 9 days. However, no significant growth delay was produced in any of the other combinations of these agents. The median growth delay was significantly reduced to 5 days when MISO was administered 3 h before BCNU, whereas MISO administered simultaneously 3,6, or 12 h after BCNU significantly enhanced delays ( 9 days). These results indicate that both MISO and 0063 may be combined with conventional therapeutic agents, in this particular case a nitrosourea, to produce an enhanced tumour response. The production of such a response appears to be nitroimidazole as well as schedule dependent.

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. M. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo. Radiat Res. 1977 Dec;72(3):469–486. [PubMed] [Google Scholar]
  2. Conroy P. J., Sutherland R. M., Passalacqua W. Misonidazole cytotoxicity in vivo: a comparison of large single doses with smaller doses and extended contact of the drug with tumor cells. Radiat Res. 1980 Jul;83(1):169–189. [PubMed] [Google Scholar]
  3. Conroy P. J., Von Burg R., Passalacqua W., Penney D. P., Sutherland R. M. Misonidazole neurotoxicity in the mouse: evaluation of functional, pharmacokinetic, electrophysiologic and morphologic parameters. Int J Radiat Oncol Biol Phys. 1979 Jul;5(7):983–991. doi: 10.1016/0360-3016(79)90604-7. [DOI] [PubMed] [Google Scholar]
  4. Hill R. P., Stanley J. A. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res. 1975 May;35(5):1147–1153. [PubMed] [Google Scholar]
  5. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  6. Katz M. E., Glick J. H. Nitrosoureas: a reappraisal of clinical trials. Cancer Clin Trials. 1979 Winter;2(4):297–316. [PubMed] [Google Scholar]
  7. Mohindra J. K., Rauth A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976 Mar;36(3):930–936. [PubMed] [Google Scholar]
  8. Moore B. A., Palcic B., Skarsgard L. D. Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells. Radiat Res. 1976 Sep;67(3):459–473. [PubMed] [Google Scholar]
  9. Olive P. L., Durand R. E. Activation of radiosensitizers by hypoxic cells. Br J Cancer Suppl. 1978 Jun;3:124–128. [PMC free article] [PubMed] [Google Scholar]
  10. Oliverio V. T. Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep 3. 1973 May;4(3):13–20. [PubMed] [Google Scholar]
  11. Roizin-Towle L., Hall E. J. Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer. 1978 Feb;37(2):254–260. doi: 10.1038/bjc.1978.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Siemann D. W., Hill R. P., Bush R. S. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):903–911. doi: 10.1016/0360-3016(77)90188-2. [DOI] [PubMed] [Google Scholar]
  13. Sridhar R., Koch C., Suterland R. Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model. Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1149–1157. doi: 10.1016/0360-3016(76)90088-2. [DOI] [PubMed] [Google Scholar]
  14. Stratford I. J., Adams G. E. Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer. 1977 Mar;35(3):307–313. doi: 10.1038/bjc.1977.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sutherland R. M., Bareham B. J., Reich K. A. Cytotoxicity of hypoxic cell sensitizers in multicell spheroids. Cancer Clin Trials. 1980 Spring;3(1):73–83. [PubMed] [Google Scholar]
  16. Sutherland R. M., Eddy H. A., Bareham B., Reich K., Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1225–1230. doi: 10.1016/0360-3016(79)90643-6. [DOI] [PubMed] [Google Scholar]
  17. Sutherland R. M. Selective chemotherapy of noncycling cells in an in vitro tumor model. Cancer Res. 1974 Dec;34(12):3501–3503. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES